Bli medlem
Bli medlem

Du är här


Biovica International AB: Redeye Initiates Coverage of Biovica

Redeye initiates coverage of cancer diagnostics firm Biovica with base
case of SEK 24. The shares have spiked some 140 percent YTD on the
back of increasing investor optimism ahead of a possible US launch
next year. While we see room for a slight pull-back short-term, a
potential marketing approval in the US for blood-based cancer
diagnostic test DiviTum within the next 6-12 months is a major
catalyst for significant further upside to our valuation. Ongoing
clinical validation to complete the submission to the FDA could
provide important clues already in the next few months.

Read more and download the Research Update:
Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.